Series  RIKB 38 0215 RIKS 50 0915
Settlement Date  09/23/2026 09/23/2026
Total Amount Allocated (MM)  1,780 3,555
All Bids Awarded At (Price / Yield)  95.735 / 7.050 111.920 / 2.810
Total Number of Bids Received  23 20
Total Amount of All Bids Received (MM)  3,860 5,635
Total Number of Successful Bids  14 7
Number of Bids Allocated in Full  14 7
Lowest Price / Highest Yield Allocated  95.735 / 7.050 111.920 / 2.810
Highest Price / Lowest Yield Allocated  96.000 / 7.010 112.220 / 2.794
Lowest Price / Highest Yield Allocated in Full  95.735 / 7.050 111.920 / 2.810
Weighted Average of Successful Bids (Price/Yield)  95.804 / 7.040 112.089 / 2.801
Best Bid (Price / Yield)  96.000 / 7.010 112.220 / 2.794
Worst Bid (Price / Yield)  95.550 / 7.070 111.150 / 2.852
Weighted Average of All Bids Received (Price / Yield)  95.743 / 7.050 111.943 / 2.809
Percentage Partial Allocation (Approximate)  100.00 % 100.00 %
Bid to Cover Ratio  2.17 1.59

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a quarterly ordinary dividend of $0.6175 per share of common stock, which is the equivalent of an annualized dividend of $2.47 per share. The dividend is payable in cash on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

The board of directors also declared the regular quarterly dividend on the company’s Series I Preferred Stock for the period July 15, 2026 through October 14, 2026 of $0.40625 per share, which is the equivalent of an annualized dividend of $1.625 per share. The dividend is payable in cash on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2026, SL Green held interests in 54 buildings totaling 30.6 million square feet, which included ownership interests in 29.2 million square feet and 1.4 million square feet securing debt and preferred equity investments, excluding fund investments, and managed 4 buildings totaling 0.9 million square feet owned by third parties.

Forward Looking Statement

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, including such matters as future capital expenditures, dividends and acquisitions (including the amount and nature thereof), development trends of the real estate industry and the New York metropolitan area markets, occupancy, business strategies, expansion and growth of our operations and other similar matters, are forward-looking statements. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

PRESS CONTACT
slgreen@berlinrosen.com

SLG – DIV

– FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts –

– Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families –

CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultragenyx Pharmaceutical Inc., on the U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, a gene therapy for the treatment of patients with Sanfilippo syndrome type A (mucopolysaccharidosis IIIA, or MPS IIIA), a rare and progressive neurodegenerative lysosomal storage disorder.

FAYUVI originated from pioneering research conducted by Drs. Haiyan Fu and Douglas McCarty at The Ohio State University and Nationwide Children’s Hospital and was subsequently advanced through clinical development by Abeona Therapeutics as ABO-102. In 2022, Abeona entered into an out-licensing agreement with Ultragenyx granting the company global development and commercialization rights to the program.

“FDA approval of FAYUVI represents an extraordinary milestone for patients and families affected by Sanfilippo syndrome type A, a devastating disease that has lacked effective therapeutic options,” said Vish Seshadri, Chief Executive Officer of Abeona Therapeutics. “The journey to this achievement is a testament to years of scientific innovation and determination across multiple organizations. Abeona was privileged to help advance this program from its academic origins into clinical development, generating the foundational data that supported its continued progress. We are grateful that Ultragenyx continued its advancement through regulatory approval and commend everyone involved in bringing this important therapy to patients.”

The approval of FAYUVI also represents a meaningful value-creation event for Abeona. Pursuant to its licensing agreement with Ultragenyx, Abeona is eligible to receive certain commercial milestone payments and royalties tied to future product sales.

About the FAYUVI development history
Abeona initially advanced the FAYUVI program through critical preclinical and clinical development stages, demonstrating proof-of-concept and establishing safety and efficacy profiles in clinical studies. To ensure the program received the substantial resources required for late-stage development, regulatory filing, and eventual commercialization, Abeona out-licensed the asset to Ultragenyx in May 2022.

About MPS IIIA (Sanfilippo Syndrome Type A)
MPS IIIA is a devastating, progressive, and fatal pediatric neurodegenerative disease caused by a deficiency of the enzyme N-sulfoglucosamine sulfohydrolase, (SGSH), which leads to the accumulation of heparan sulfate in cells throughout the body, particularly in the central nervous system. Children with MPS IIIA experience severe developmental regression, loss of motor skills, and premature death, creating an urgent, high-unmet medical need. FAYUVI is designed to deliver a functional copy of the SGSH gene to the central nervous system via an AAV9 viral vector, addressing the root genetic cause of the disease.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to our ability to maintain existing and obtain additional regulatory approvals of ZEVASKYN® and any future product candidates; our ability to successfully commercialize and market ZEVASKYN® and any future product candidates, if approved, and the timing of any commercialization and marketing efforts; our ability to manufacture sufficient batches of ZEVASKYN® to meet demand; our ability to manufacture ZEVASKYN® batches that meet certain product release specifications that were required by FDA at the time of BLA approval and implemented based on a limited clinical dataset; the FDA’s willingness to revise such release specifications to reflect real-world manufacturing experience; our ability to manufacture from provided biopsy material a ZEVASKYN® batch for which revenue may ultimately be recognized, which depends on such factors as qualified treatment centers obtaining biopsy samples from ZEVASKYN® patients of sufficient quality to act as starting material for manufacturing ZEVASKYN®, patient-to-patient variability in cell growth during the ZEVASKYN® manufacturing process, patient health deterioration in close proximity to ZEVASKYN® treatment such that treatment is no longer possible, and expiration of ZEVASKYN®’s 84-hour shelf-life before surgical application of ZEVASKYN® can be performed; our ability to activate additional qualified treatment centers to administer ZEVASKYN® on patients; the ability of qualified treatment centers to enroll patients for treatment or administer ZEVASKYN® on patients; the ability of our partners to obtain FDA approval and generate revenue from partnered programs and our ability to collect associated royalty and milestone payments; our ability submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials; our ability to access additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders; the potential impact of unpredicted changes in the structure and/or administration of the United States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once approved; our ability to meet our obligations contained in license agreements to which we are party; and macroeconomic uncertainty resulting from changes to U.S. trade policy, including current or future tariffs or other trade restrictions.

CONTACT: Contacts:
Investor and Media:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC) today announced that its subsidiary, ReadyCap Holdings II, LLC (the “Issuer”), has priced a private placement of $225.0 million in aggregate principal amount of 10.00% Senior Secured Notes due 2031 (the “New Notes”). Additionally, ReadyCap Holdings, LLC (“RCH”), a subsidiary of the Company, issued a notice of redemption for the entire $350.0 million outstanding aggregate principal amount of the 4.50% Senior Secured Notes due 2026 (the “Existing Notes”).

The New Notes were priced at 99.5% of principal amount and are expected to close on September 28, 2026. Net proceeds, together with available cash, will be used to redeem the Existing Notes in full at 100% of principal amount plus accrued and unpaid interest. The transaction retires $350.0 million of corporate debt maturing this year, funds approximately two-thirds of that repayment with new capital maturing in 2031 and reduces corporate secured debt outstanding by $125 million.

The redemption of the Existing Notes will complete a material milestone of the Company’s balance sheet repositioning program announced in the fourth quarter of 2025. Over the course of the plan, Ready Capital will have generated approximately $2.3 billion of cash; repaid $1.7 billion of asset-level financing; and retired $549 million of corporate debt. Following the redemption of the Existing Notes, the Company’s sole remaining 2026 corporate debt maturity will be $100.0 million due in November 2026, which the Company expects to repay at maturity from cash on hand.

The Company expects to shift its emphasis from liquidity generation to earnings growth. It intends to deploy capital into current market-yielding originations across its core commercial real estate debt and small business lending platforms.

“In the fourth quarter of 2025, we embarked on a plan to de-lever, generate significant liquidity and reset the balance sheet, and with the $350 million redemption that work is substantially complete,” said Thomas Capasse, Ready Capital’s Chairman and Chief Executive Officer. “This execution demonstrates that investors continue to underwrite the quality of our collateral and the credibility of our business plan. From here our emphasis moves from managing liquidity to growing earnings behind our core CRE and SBA franchises.”

Piper Sandler & Co. acted as the placement agent for the offering. Alston & Bird LLP served as counsel for the Company, and Ropes & Gray LLP served as counsel for the placement agent.

About Ready Capital Corporation

Ready Capital Corporation (NYSE: RC) is a multi-strategy real estate finance company that originates, acquires, finances and services lower-to-middle-market investor and owner occupied commercial real estate loans. The Company specializes in loans backed by commercial real estate, including agency multifamily, investor, construction, and bridge as well as U.S. Small Business Administration loans under its Section 7(a) program. Headquartered in New York, New York, the Company employs over 400 professionals nationwide.

No Offer or Solicitation

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, nor does it constitute a notice of redemption of the Existing Notes. The New Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. The New Notes were offered and will be sold in a private placement in reliance on Section 4(a)(2) of the Securities Act to a limited number of institutional accredited investors as defined in Rule 501(a) of Regulation D. Any redemption of the Existing Notes will be made solely pursuant to the applicable notice of redemption and governing documents.

Safe Harbor Statement

This press release contains statements that constitute “forward-looking statements,” as such term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements; the Company can give no assurance that its expectations will be attained. These statements include, without limitation, statements regarding the expected closing of the New Notes offering, the intended redemption of the Existing Notes and the timing thereof, the expected repayment of the Company’s November 2026 corporate debt maturity, the completion of the Company’s balance sheet repositioning plan, and the Company’s expectations regarding future leverage, originations and earnings. Factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, applicable regulatory changes; general volatility of the capital markets; changes in the Company’s investment objectives and business strategy; the availability of financing on acceptable terms or at all; the availability, terms and deployment of capital; the availability of suitable investment opportunities; changes in the interest rates or the general economy; increased rates of default and/or decreased recovery rates on investments; changes in interest rates, interest rate spreads, the yield curve or prepayment rates; changes in prepayments of the Company’s assets; the degree and nature of competition, including competition for the Company’s target assets; and other factors, including those set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K filed with the SEC, and other reports filed by the Company with the SEC, copies of which are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Investor Relations
Ready Capital Corporation
212-257-4666
InvestorRelations@readycapital.com 
Additional information can be found on the Company’s website at www.readycapital.com. 

AltLens is engineered to measure portfolio risk based on the historical behavior of private markets and make advanced, institutional-level analytics accessible to family offices and small institutional investors

DALLAS, Sept. 18, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (together with its subsidiaries, the “Company” or “Beneficient”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that it plans to launch AltLens in the fourth quarter of calendar year 2026. AltLens is an alternative asset portfolio analytics and risk platform developed for family offices and small institutional investors. AltLens is designed to help investment teams maintain, organize, and analyze their alternative asset portfolios and assess exposures, allocations against targets and limits, portfolio risk, concentration, and stress-test results.

“Private markets have become too large and too important to the investors we serve for family offices and smaller institutions to rely principally on spreadsheets and public-market proxies to understand portfolio risk,” said James G. Silk, Chief Executive Officer. “We developed AltLens to make sophisticated alternative asset analysis practical for these investors and managers by applying sophisticated risk models to complex private-market data and translating the results into clear analytics that can inform portfolio decisions.”

AltLens maps each portfolio position to specific private-market risk segments defined by asset class, strategy, geography, and sector. For each segment, AltLens maintains a historical series of quarterly returns based on historical private market performance. From these historical returns, AltLens is designed to calculate volatility, beta, value-at-risk, correlation, and concentration metrics. By incorporating historical private-fund performance, the methodology is designed to reflect how private assets have actually behaved rather than analyzing them through a proxy of select publicly traded securities.

The need for alternative asset analytics is expected to grow with the market. Preqin has forecast that alternatives assets under management will reach approximately $29 trillion globally by 2029. As alternative assets account for a larger share of portfolios, family offices and smaller institutions face a growing need for consistent, defensible analysis to support portfolio oversight and investment decisions.

AltLens will also provide historical and hypothetical stress-testing capabilities. Historical scenarios will simulate how a private-market portfolio would perform during markets analogous to the 2008-09 financial crisis, the 2000-03 technology downturn, and the 2021-22 inflationary and rising-interest-rate environment. Users will also be able to model custom hypothetical equity-market declines and interest-rate shocks and evaluate their projected effects by asset class and individual position.

The platform is organized into a set of analytical “lenses” designed to address key portfolio oversight questions: What does the portfolio hold, and how do its allocations compare with applicable targets and limits? What are its principal sources of risk, and where is it concentrated? How might it perform under select stress scenarios? AltLens will deliver the results through dashboards and exportable reports. Using a quarterly portfolio snapshot, the platform is designed to complement a customer’s existing accounting and administration systems.

“Family offices and smaller institutions should not need an enterprise-scale system or a lengthy implementation to conduct sophisticated portfolio risk analysis for alternative assets,” Silk said. “AltLens is designed to fit their quarterly workflow by translating a portfolio snapshot into clear risk and concentration analysis and reports that support investment committee and board decision-making.”

AltLens is part of Beneficient’s broader alternative asset technology platform, under which Beneficient is developing AltSignal, an AI-enabled alternative asset diligence engine, and AltDeal, an enterprise acquisition analysis engine. Beneficient expects to make AltLens available to family offices and small institutional investors in the fourth quarter of calendar year 2026.

About Beneficient

Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and value-added services for their funds – with solutions that could help them unlock the value in their alternative assets.

Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner.

For more information, visit trustben.com or follow us on LinkedIn.

Contacts

Matt Kreps: 214-597-8200, mkreps@darrowir.com

Michael Wetherington: 214-284-1199, mwetherington@darrowir.com

Investor Relations: investors@beneficient.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the planned launch of AltLens in the fourth quarter of calendar year 2026; the expected timing of AltLens’s availability to family offices and small institutional investors; the designed capabilities of AltLens; the anticipated benefits of AltLens and Beneficient’s broader alternative asset technology platform; the expected growth of the alternative asset market and related demand for portfolio analytics and risk-management tools; and the development and anticipated capabilities of AltSignal and AltDeal. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.

Important factors that could cause actual results to differ materially from those expressed in the forward-looking statements include, among others, risks relating to the timing, development, launch and functionality of AltLens; the risk that the Company is unable to develop, commercialize, or expand AltLens, AltSignal, AltDeal, or its broader alternative asset technology platform; and the other risks, uncertainties, and factors set forth under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q, and the risks and uncertainties contained in the Company’s Current Reports on Form 8-K.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

The legendary Chicago restaurant brand will bring its iconic menu items – including its beloved Char-Broiled Burgers – to Buford as it continues its Georgia expansion, marking its second restaurant in the state following the 2025 opening of its Kennesaw location

OAK BROOK, Ill., Sept. 18, 2026 (GLOBE NEWSWIRE) — In honor of National Cheeseburger Day, Portillo’s (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of unrivaled Chicago-style street food, today announced plans to open a new restaurant in Buford, Georgia, in 2027. The new restaurant will mark Portillo’s second location in Georgia, following the November 2025 opening of its Kennesaw restaurant.

The new Portillo’s will be located at the intersection of Buford Highway (Highway 20) and Mall of Georgia Boulevard. The approximately 4,900-square-foot restaurant will offer seating for nearly 100 guests indoors, plus an additional 20 seats on an outdoor patio. Designed to serve guests however they choose to enjoy Portillo’s, the restaurant will also feature the brand’s signature double drive-thru lanes, Portillo’s Pick-Up shelves, and Grab and Go area for added convenience.

“We’ve felt an incredible welcome from Georgia guests since first opening in Kennesaw last year, and we’re excited to bring even more of what makes Portillo’s special to Buford,” said Brett Patterson, President and Chief Executive Officer of Portillo’s. “As we continue to grow, we’re being thoughtful about where and how we expand, and Buford is a great next step for us. We can’t wait to introduce even more Georgians to the craveable food and one-of-a-kind experience that have made Portillo’s a destination for more than 60 years.”

When Portillo’s Buford opens in 2027, guests can expect to enjoy Portillo’s signature menu of Chicago-style favorites, including Chicago-Style Hot Dogs, famous Italian Beef Sandwiches, Char-Broiled Burgers and Portillo’s classic Chocolate Cake. And with the announcement landing on National Cheeseburger Day, there’s no better time to celebrate the Char-Broiled Burgers that will soon be headed to Buford.

Portillo’s fans can sign up for the latest details about the new Buford restaurant, including hiring opportunities and opening announcements at Portillos.com.

Fans can also join Portillo’s Perks, the brand’s loyalty program, for exclusive offers, experiences and other rewards at Portillos.com/perks. New Perks members will also receive a free large French fry with their first order of $5 or more. Terms and exclusions apply.*

For more information on this restaurant and others, please visit portillos.com or follow Portillo’s on Facebook, X and Instagram, and TikTok.

*New Perks members only. Terms and exclusions apply. Limit 1. See Portillos.com/Perks for more details.

ABOUT PORTILLO’S
Portillo’s (NASDAQ: PTLO) is a one-of-a-kind brand that has grown from a small hot dog trailer in Chicago to more than 100 restaurants across 11 states. Known for its unique menu of craveable Italian beef sandwiches, Chicago-style hot dogs, char-grilled burgers, fresh salads and iconic chocolate cake, Portillo’s is beloved in both its home of Chicagoland and across new and growing markets. Portillo’s operates a company-owned model of not just restaurants – but experience-focused destinations that blend dine-in, drive-thru, takeout and delivery to serve our guests with the food they crave. And now, after six decades of success and counting, Portillo’s is on a mission to bring its iconic food and unforgettable dining experience to guests across the country.

Guests can join Portillo’s Perks, the brand’s loyalty program, at Portillos.com/perks to earn and redeem delicious rewards. Every visit brings fans closer to exclusive perks, badges and surprise offers. Fans can also download the Portillo’s App for iOS or Android or visit Portillo’s website to order ahead for pickup or delivery and get the best dill on these bun-believably delicious Chicago-style favorites and more. Plus, Portillo’s ships its craveworthy food to all 50 states via its website.

MEDIA CONTACT
ICR
PortillosPR@icrinc.com

Highlights

  • Maiden 2,500m diamond drill program at Luanshya West scheduled to commence during the week of 21 September, with completion expected by end-of-year
  • Drilling will test up to four priority targets, targeting vertical depths of 100-250m
  • Further exploration underway at Mpongwe to refine existing and new targets, with approximately 3,000 soil samples planned to be collected by end of year
  • Agreement to increase Koryx’ ownership from 51% to 80%, with no remaining contractual expenditure commitments to complete earn-in

LUXEMBOURG, Sept. 18, 2026 (GLOBE NEWSWIRE) — Koryx Copper S.A. (TSX:KRY.V) (NSX:KYX) (OTCQX:KRYXF)   (“Koryx” or the “Company”) is pleased to announce it has entered into an amended and restated option agreement (the “A&R Option Agreement”) with World Class Mineral Ventures Limited (“WCMV”). Pursuant to the A&R Option Agreement, Koryx, through its wholly owned subsidiary, Koryx Copper Mauritius, will increase its ownership interest in Koryx Copper Zambia Ltd (“KCZ”) from 51% to 80% (the “Transaction”). KCZ holds 100% of two large-scale exploration licenses at the Luanshya West Project (LEL 23246) and the Mpongwe Project (LEL 23248) located in the Zambian Copperbelt (the “Licenses”).

Heye Daun, Koryx Copper’s President & CEO commented: “While the Haib project in Namibia remains our primary focus, our Zambian exploration programs have made significant progress since Koryx’ management transition. Detailed magnetic surveying, soil sampling, and pitting at Luanshya West have helped identify and prioritise four targets which we will begin drilling this month, while regional sampling and our reassessment of exploration data at Mpongwe have confirmed new targets for infill sampling to be completed later this year.

We continue to be encouraged by the exploration progress and resource potential in Zambia and have therefore decided to accelerate our ownership in Koryx Copper Zambia Ltd which holds both Luanshya West and Mpongwe. This gives us greater flexibility to assess our strategic options to monetize the Zambian Projects, while continuing to retain our operational and financial emphasis on the advancement of Haib.”

Amended and Restated Option Agreement

The A&R Option Agreement amends and restates Koryx’ 2022 earn-in agreement with WCMV (the “Initial Agreement”). Under the Initial Agreement, Koryx could earn an interest of up to 80% in three large-scale exploration licenses held by WCMV (LEL 23246, LEL 23247 and LEL 23248, collectively, the “Initial Licenses”). Koryx had acquired a 51% interest in the Initial Licenses by way of earn-in. Increasing Koryx’ interest from 51% to 80% originally required a further US$3 million in exploration expenditure over three years, with approximately US$1.1 million spent to date, together with US$90,000 in cash and additional share payments. The Company had already relinquished LEL 23247, leaving Luanshya West and Mpongwe as the two projects covered by the amended agreement.

On closing, the A&R Option Agreement will increase Koryx’ interest in these two projects to an effective 80%, indirectly through its 80% ownership of KCZ, and eliminate the remaining contractual earn-in expenditure commitments. The aggregate consideration payable by Koryx at closing of the Transaction is: (a) US$200,000 in cash; and (b) 80,000 common shares in the capital of Koryx (the “Common Shares”) at a deemed price of C$3.50 per Common Share, subject to any adjustment required by the TSX Venture Exchange (the “Exchange”). The amended agreement also provides a conditional right for Koryx to acquire the remaining 20% interest for US$400,000 if WCMV elects not to contribute its share of future project funding.

The Transaction constitutes an “Expedited Acquisition” in accordance with Exchange policies. The Common Shares issuable under the A&R Option Agreement will be subject to a hold period of four months and one day pursuant to Canadian securities laws. Closing of the Transaction is subject to customary closing conditions, including acceptance by the Exchange, and is expected to occur no later than the outside date of September 30, 2026. No finder’s fees are payable.

Zambia Projects Exploration Update

The Company is pleased to provide an update on exploration activities in Zambia, where fieldwork has commenced on both the Luanshya West (license 23246-HQ-LEL) and Mpongwe (23248-HQ-LEL) projects.

At Luanshya West an initial diamond drill program will commence before the end of September 2026 aimed at testing three or four targets with 2,500m of drilling (see Figure 1 below). Drill holes will be inclined and test surface geochemistry anomalies, induced polarization (IP) chargeability and resistivity features and structural targets to a vertical depth of 100m to 250m. The drill program is expected to be completed by mid-December this year.

At the Mpongwe project, follow up and in-fill soil sampling will be completed on targets identified during 2025 sampling programs (at Lwabufubu, MP1 and MP2 targets), as well as completing regional soil sampling in the western parts of the license which could not be sampled in 2025. The sampling is expected to be completed in early November and will total about 3,000 samples. Results and possible early onset of the rainy season will determine whether follow up shallow drilling will be carried out in late 2026 or be delayed until 2027.

Figure 1

Figure 1: Luanshya West license with four targets to be drill tested (highlighted as black boxes)

Quality Assurance / Quality Control

All drill core is HQ sized at collar and reduced to NQ size in fresh rock. The core was all logged, photographed, and cut in half with a diamond saw. Half of the core was bagged and sent to ALS Laboratories Ltd. in Johannesburg, South Africa for analysis (SANAS Accredited Testing Laboratory, No. T0387) and ActLabs in Canada, while the other half was quartered with one quarter archived and stored on site for verification and reference purposes while the other quarter will be used for metallurgical test work. 33 elements are analyzed by Inductively Coupled Plasma (ICP) utilizing a 4-acid digestion and gold is assayed for using a 30g fire assay method. Duplicate samples, blanks, and certified standards are included with every batch and are actively used to ensure proper quality assurance and quality control (“QA/QC”) The QA/QC frequency is 1 in 20 for each of blanks, duplicates and standards. 

Qualified Persons

Mr. Dean Richards, BSc. (Hons) Geology, Pr.Sci.Nat., MGSSA – is the Qualified Person for the Haib Copper Project and has reviewed and approved the scientific and technical information in this news release and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr.Sci.Nat. No. 400190/08). Mr. Richards is independent of the Company and its mineral properties and is a Qualified Person for the purposes of National Instrument 43-101.

About Koryx Copper S.A.

Koryx Copper S.A. is a Luxembourg domiciled copper development Company focused on advancing its 100% owned Haib Copper Project in Namibia whilst also building a portfolio of copper exploration licenses in Zambia. Haib is a large copper porphyry deposit in southern Namibia with significant gold and molybdenum credits and a long history of exploration and project development by multiple operators.

More than 155,000m of drilling has been conducted at Haib since the 1970’s with significant exploration programs led by companies including Falconbridge (1964), Rio Tinto (1975), Teck (2014) and Koryx Copper (2021-2026). Extensive further drilling, metallurgical testing and various technical studies have been completed at Haib. Additional studies are underway aiming to demonstrate Haib as a future long-life, low-cost, low-risk open pit, sulphide milling and flotation copper project with additional heap leach potential.

Mineralisation at Haib is typical of a porphyry copper deposit and is dominantly chalcopyrite with minor bornite and chalcocite present and only minor secondary copper minerals at surface due to the arid environment. Haib is one of only a few examples of a Paleoproterozoic porphyry copper deposit in the world. Due to its age, the deposit has been subjected to multiple metamorphic and deformation events but still retains many of the classic mineralisation and alteration features typical of these deposits.

Further details of the Haib Copper Project are available in the technical report titled “March 2026 Mineral Resource Estimate Haib Copper Project, Namibia, National Instrument 43-101 Technical Report” dated effective March 16, 2026. The report and other information are available on the Company’s website at www.koryxcopper.com and under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Additional information is also available by contacting the Company:

Aideen McDermott
Investor Relations
amcdermott@koryxcopper.com
+1-416-837-7680

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the future or prospects of the Haib project or the Company, including prospective production rates and life-of-mine, the timing of publishing a PFS, the commencement of trading of the Shares under the new Company name, and the effective date of the new CUSIP and ISIN assigned to the Shares. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect “, “is expected “, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management discussion and analysis. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9aa54f1-a838-43b0-8d99-62c219081372

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of September 14, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 64,850 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 21,350 shares of Ocular’s common stock. The stock option awards have an exercise price of $10.72 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce the launch of 1964 Supply Co.™ (“1964”) full spectrum vapes in the United Kingdom through its distribution partnership with 4C LABS.

“The response to 1964 in the U.K. has demonstrated that there is growing demand for premium medical cannabis products in international markets,” said Margaret Brodie, Chief Executive Officer of Rubicon Organics. “With patient numbers in the U.K. expected to grow 40% this year1, and vape offerings increasingly popular, the launch of 1964 full spectrum vapes builds on the success of the brand in the U.K. and further strengthens our position in a rapidly expanding market.”

1964 first entered the U.K. market with its award-winning Blue Dream and Stinky Pinky flower strains in April. Rubicon Organics has since expanded the brand’s flower offerings to include its Apples and Bananas flower, and the launch of full spectrum vapes marks the next step in developing the 1964 portfolio for the U.K. medical cannabis market. By extending its premium genetics into vape formats, 1964 provides patients with additional consumption options beyond flower while maintaining the quality, consistency, and cultivar-driven experience associated with the brand.

1964 is one of Rubicon Organics’ flagship brands and one of Canada’s leading premium cannabis brands, having won numerous awards including Brand of the Year for the last two years at the industry’s prestigious KIND Awards. The brand is inspired by classic legacy genetics and designed to deliver genuine, high-quality cannabis with a focus on consistency and trust.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organic, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

ABOUT 4C LABS

4C LABS Ltd. is a privately held Canadian medical cannabis company focusing on providing pharmacies & clinics with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co.

CONTACT INFORMATION

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding continued patient demand for premium medical cannabis products; the continued availability of regulatory approvals and import permits; the ability of 4C LABS and other third parties to distribute the Company’s products; stable market conditions; the Company’s ability to maintain product quality, supply and production levels; and the Company’s ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the Company’s international growth strategy; the expansion and development of the 1964 Supply Co.™ portfolio in the United Kingdom; the availability, distribution and commercial performance of the Company’s products in the U.K. medical cannabis market; demand for premium medical cannabis products in international markets; the continuation and success of the Company’s distribution partnership with 4C LABS; the Company’s ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company’s production capacity, revenue growth opportunities and strategic initiatives.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, and competition; changes in laws, regulations and regulatory policies governing medical cannabis in Canada, the United Kingdom and other international markets; reliance on third-party distributors and service providers; pricing pressures; product recalls; supply chain disruptions; foreign exchange fluctuations; challenges in maintaining required certifications and quality standards; access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

1 Prohibition Partners, UK Medical Cannabis Market Update 2026 (June 2026)

McFarlane Lake Mining joins five other companies from Michael Gentile’s portfolio across a five-city program running October 19 through 23, 2026

TORONTO, Sept. 18, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, and the Michael Gentile Mining & Metals European Roadshow, continuing to Paris, Frankfurt, Zurich, and Munich from October 20 through 23. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. and supported by flagship sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“We’re excited to bring the Juby Gold story to European investors,” said Mark Trevisiol, Chief Executive Officer, President and Director of McFarlane. “With the significant resource growth we have demonstrated at Juby and our recently completed financing supporting continued drilling and project advancement, we have strong momentum heading into this program. This is an excellent opportunity to introduce Juby’s scale and potential to a broader global investor audience.”

McFarlane Lake Mining is one of six companies from Gentile’s portfolio participating in the full five-city program. The program opens with the Forum on Monday, October 19 at 116 Pall Mall in Mayfair, London, bringing together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio.

The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor.Events. Crux Investor serves as the Forum’s media sponsor.

The Roadshow then continues to Paris (October 20), Frankfurt (October 21), Zurich (October 22), and Munich (October 23), where McFarlane Lake Mining will take part in structured one-on-one investor meetings and a hosted lunch presentation in each city, including a keynote by Gentile.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Investor Registration

Investor registration is now open for events in all five cities. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About McFarlane Lake Mining Limited

McFarlane Lake is a gold exploration company focused on exploring and advancing the Juby Gold project near Gowganda, Ontario. The Juby Gold project has a (NI 43-101) inferred resource of 5.06 million ounces of gold at 0.87 gpt contained in 180.67 million tonnes and Indicated resources of 1.14 million ounces of gold at 0.95 gpt contained in 37.17 million tonnes, using a long-term gold price of US$3,600/oz. These resources have an effective date of August 14, 2026. Sensitivities performed at higher gold prices – US$4,600/oz gold- the deposit holds 5.40 million inferred ounces at 0.85 gpt gold and 1.20 million indicated ounces at 0.93 gpt gold.

The full technical report on these resources will be issued within 45 days of the Company’s MRE announcement. The technical report will be issued by BBA E&C Inc., an independent organization from McFarlane Lake Mining. McFarlane is currently planning to perform exploration drilling on the Juby Gold Project as well as other study work to advance the development of the property.

In addition to the Juby Gold Project, McFarlane holds a portfolio of 100%-owned gold assets across Ontario, including the past-producing McMillan Gold Mine and Mongowin properties located approximately 70 km west of Sudbury and the Michaud/Munro properties located 115 km east of Timmins. McFarlane is a reporting issuer in Ontario, British Columbia, and Alberta.

Readers are cautioned to refer to the “Cautionary Note Regarding Forward-Looking Information” and all other disclaimers included in this news release for important information regarding the limitations and verification status of the data presented above and elsewhere herein.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

Further Information

For further information regarding McFarlane Lake, please contact:

Bryan Baritot, Investor Relations
McFarlane Lake Mining Limited
investors@mcfarlanelakemining.com

Mark Trevisiol
Chief Executive Officer, President and Director
McFarlane Lake Mining Limited
705 665 5087
mtrevisiol@mcfarlanelakemining.com

To learn more, visit: https://mcfarlanelakemining.com/

Additional information on McFarlane Lake can be found by reviewing its profile on SEDAR+ at www.sedarplus.ca.

Cautionary Statement Regarding Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of Canadian securities legislation, including, but not limited to, statements regarding the Company’s plans with respect to the Company’s projects and the timing related thereto, the merits of the Company’s projects, the Company’s objectives, plans and strategies, the tax treatment of the FT Shares, the use of proceeds of the Offering, and other matters. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,”, “strategy”, “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the CSE, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include the risk of accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, or the possibility that the Company may not be able to secure permitting and other agency or governmental clearances, necessary to carry out the Company’s exploration plans, risks of political uncertainties and regulatory or legal changes in the jurisdictions where the Company carries on its business that might interfere with the Company’s business and prospects. The reader is urged to refer to the Company’s reports, publicly available through the Canadian Securities Administrators’ System for Electronic Data Analysis and Retrieval + (SEDAR+) at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects.

Cautionary Statement on Mineral Resources

This news release uses the terms indicated and inferred mineral resources as a relative measure of the level of confidence in the resource estimate. Readers are cautioned that mineral resources are not mineral reserves and that the economic viability of resources that are not mineral reserves has not been demonstrated. The mineral resource estimates disclosed in this news release may be materially affected by geology, environmental, permitting, legal, title, socio-political, marketing or other relevant issues. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to an indicated or measured mineral resource category; however, it is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. The mineral resource estimate is classified in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum’s “CIM Definition Standards on Mineral Resources and Mineral Reserves” incorporated by reference into NI 43-101. Under NI 43-101, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies or economic studies except for preliminary economic assessments. Readers are cautioned not to assume that further work on the stated resources will lead to mineral reserves that can be mined economically.

Qualified Person

Mark Trevisiol, P.Eng. (ON), President and CEO of McFarlane Lake Mining and a non-independent Qualified Person as defined by National Instrument 43-101, has approved and verified the technical information used in this news release. The mineral resource estimate referenced herein was prepared by BBA E&C Inc., an independent organization from McFarlane Lake Mining.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.